Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma.
Identifieur interne : 002559 ( PubMed/Checkpoint ); précédent : 002558; suivant : 002560Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma.
Auteurs : Zhan Zhang [République populaire de Chine] ; Yi-Wu Xie ; Jiling Hong ; Xin Zhang ; Sui Yi Kwok ; Xiaowu Huang ; Sai Wah Wong ; Bing-Lou WongSource :
- Transfusion [ 0041-1132 ] ; 2005.
Descripteurs français
- KwdFr :
- Anticorps antiviraux (sang), Convalescence, Dimérisation, Globulines (), Globulines (isolement et purification), Humains, Injections veineuses, Plasma sanguin (immunologie), Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (sang), Technique d'immunofluorescence indirecte, Test ELISA, Tests de neutralisation, Virus du SRAS (immunologie).
- MESH :
- immunologie : Plasma sanguin, Syndrome respiratoire aigu sévère, Virus du SRAS.
- isolement et purification : Globulines.
- sang : Anticorps antiviraux, Syndrome respiratoire aigu sévère.
- Convalescence, Dimérisation, Globulines, Humains, Injections veineuses, Syndrome respiratoire aigu sévère, Technique d'immunofluorescence indirecte, Test ELISA, Tests de neutralisation.
English descriptors
- KwdEn :
- Antibodies, Viral (blood), Convalescence, Dimerization, Enzyme-Linked Immunosorbent Assay, Fluorescent Antibody Technique, Indirect, Globulins (chemistry), Globulins (isolation & purification), Humans, Injections, Intravenous, Neutralization Tests, Plasma (immunology), SARS Virus (immunology), Severe Acute Respiratory Syndrome (blood), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control).
- MESH :
- chemical , blood : Antibodies, Viral.
- chemical , chemistry : Globulins.
- chemical , isolation & purification : Globulins.
- blood : Severe Acute Respiratory Syndrome.
- immunology : Plasma, SARS Virus, Severe Acute Respiratory Syndrome.
- prevention & control : Severe Acute Respiratory Syndrome.
- Convalescence, Dimerization, Enzyme-Linked Immunosorbent Assay, Fluorescent Antibody Technique, Indirect, Humans, Injections, Intravenous, Neutralization Tests.
Abstract
Severe acute respiratory syndrome (SARS) is a new infectious disease caused by the SARS virus. Current first-line treatments are experimental, and their effectiveness remains open to question. For more effective treatment and prevention of SARS, human SARS hyperimmune globulins for intravenous (IV) injection were purified in this study.
DOI: 10.1111/j.1537-2995.2005.00179.x
PubMed: 15987362
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:15987362Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma.</title><author><name sortKey="Zhang, Zhan" sort="Zhang, Zhan" uniqKey="Zhang Z" first="Zhan" last="Zhang">Zhan Zhang</name><affiliation wicri:level="1"><nlm:affiliation>Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong</wicri:regionArea><wicri:noRegion>Guangdong</wicri:noRegion></affiliation></author><author><name sortKey="Xie, Yi Wu" sort="Xie, Yi Wu" uniqKey="Xie Y" first="Yi-Wu" last="Xie">Yi-Wu Xie</name></author><author><name sortKey="Hong, Jiling" sort="Hong, Jiling" uniqKey="Hong J" first="Jiling" last="Hong">Jiling Hong</name></author><author><name sortKey="Zhang, Xin" sort="Zhang, Xin" uniqKey="Zhang X" first="Xin" last="Zhang">Xin Zhang</name></author><author><name sortKey="Kwok, Sui Yi" sort="Kwok, Sui Yi" uniqKey="Kwok S" first="Sui Yi" last="Kwok">Sui Yi Kwok</name></author><author><name sortKey="Huang, Xiaowu" sort="Huang, Xiaowu" uniqKey="Huang X" first="Xiaowu" last="Huang">Xiaowu Huang</name></author><author><name sortKey="Wong, Sai Wah" sort="Wong, Sai Wah" uniqKey="Wong S" first="Sai Wah" last="Wong">Sai Wah Wong</name></author><author><name sortKey="Wong, Bing Lou" sort="Wong, Bing Lou" uniqKey="Wong B" first="Bing-Lou" last="Wong">Bing-Lou Wong</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:15987362</idno><idno type="pmid">15987362</idno><idno type="doi">10.1111/j.1537-2995.2005.00179.x</idno><idno type="wicri:Area/PubMed/Corpus">002664</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002664</idno><idno type="wicri:Area/PubMed/Curation">002664</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002664</idno><idno type="wicri:Area/PubMed/Checkpoint">002559</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002559</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma.</title><author><name sortKey="Zhang, Zhan" sort="Zhang, Zhan" uniqKey="Zhang Z" first="Zhan" last="Zhang">Zhan Zhang</name><affiliation wicri:level="1"><nlm:affiliation>Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong</wicri:regionArea><wicri:noRegion>Guangdong</wicri:noRegion></affiliation></author><author><name sortKey="Xie, Yi Wu" sort="Xie, Yi Wu" uniqKey="Xie Y" first="Yi-Wu" last="Xie">Yi-Wu Xie</name></author><author><name sortKey="Hong, Jiling" sort="Hong, Jiling" uniqKey="Hong J" first="Jiling" last="Hong">Jiling Hong</name></author><author><name sortKey="Zhang, Xin" sort="Zhang, Xin" uniqKey="Zhang X" first="Xin" last="Zhang">Xin Zhang</name></author><author><name sortKey="Kwok, Sui Yi" sort="Kwok, Sui Yi" uniqKey="Kwok S" first="Sui Yi" last="Kwok">Sui Yi Kwok</name></author><author><name sortKey="Huang, Xiaowu" sort="Huang, Xiaowu" uniqKey="Huang X" first="Xiaowu" last="Huang">Xiaowu Huang</name></author><author><name sortKey="Wong, Sai Wah" sort="Wong, Sai Wah" uniqKey="Wong S" first="Sai Wah" last="Wong">Sai Wah Wong</name></author><author><name sortKey="Wong, Bing Lou" sort="Wong, Bing Lou" uniqKey="Wong B" first="Bing-Lou" last="Wong">Bing-Lou Wong</name></author></analytic><series><title level="j">Transfusion</title><idno type="ISSN">0041-1132</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Viral (blood)</term><term>Convalescence</term><term>Dimerization</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Fluorescent Antibody Technique, Indirect</term><term>Globulins (chemistry)</term><term>Globulins (isolation & purification)</term><term>Humans</term><term>Injections, Intravenous</term><term>Neutralization Tests</term><term>Plasma (immunology)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (blood)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps antiviraux (sang)</term><term>Convalescence</term><term>Dimérisation</term><term>Globulines ()</term><term>Globulines (isolement et purification)</term><term>Humains</term><term>Injections veineuses</term><term>Plasma sanguin (immunologie)</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Syndrome respiratoire aigu sévère (sang)</term><term>Technique d'immunofluorescence indirecte</term><term>Test ELISA</term><term>Tests de neutralisation</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Globulins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>Globulins</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Plasma sanguin</term><term>Syndrome respiratoire aigu sévère</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Plasma</term><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Globulines</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Convalescence</term><term>Dimerization</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Fluorescent Antibody Technique, Indirect</term><term>Humans</term><term>Injections, Intravenous</term><term>Neutralization Tests</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Convalescence</term><term>Dimérisation</term><term>Globulines</term><term>Humains</term><term>Injections veineuses</term><term>Syndrome respiratoire aigu sévère</term><term>Technique d'immunofluorescence indirecte</term><term>Test ELISA</term><term>Tests de neutralisation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is a new infectious disease caused by the SARS virus. Current first-line treatments are experimental, and their effectiveness remains open to question. For more effective treatment and prevention of SARS, human SARS hyperimmune globulins for intravenous (IV) injection were purified in this study.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15987362</PMID><DateCompleted><Year>2005</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2005</Year><Month>06</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0041-1132</ISSN><JournalIssue CitedMedium="Print"><Volume>45</Volume><Issue>7</Issue><PubDate><Year>2005</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Transfusion</Title><ISOAbbreviation>Transfusion</ISOAbbreviation></Journal><ArticleTitle>Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma.</ArticleTitle><Pagination><MedlinePgn>1160-4</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Severe acute respiratory syndrome (SARS) is a new infectious disease caused by the SARS virus. Current first-line treatments are experimental, and their effectiveness remains open to question. For more effective treatment and prevention of SARS, human SARS hyperimmune globulins for intravenous (IV) injection were purified in this study.</AbstractText><AbstractText Label="STUDY DESIGN AND METHODS" NlmCategory="METHODS">A combination of cold ethanol precipitation and ion-exchange chromatography was used to process pooled SARS convalescent plasma samples. Virus inactivation and removal approaches were taken to ensure safety.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The purified hyperimmune globulins were formulated as a 5 percent solution, with an antibody titer specifically against the SARS virus of 1:83, 1:1600, and 1:200, as determined by enzyme-linked immunosorbent assay, immunofluorescence assay, and neutralizing antibody test, respectively. The purity of the SARS hyperimmune globulins was 99.0 percent, and the monomer and dimer content was 100 percent. Other variables analyzed met the Chinese Requirements of Biologics for IV immune globulin. The SARS hyperimmune globulins prepared were subsequently approved for clinical evaluation by the Chinese National Institute for the Control of Pharmaceutical & Biological Products.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">IV-injectable, purified, and concentrated human SARS hyperimmune globulins were prepared from pooled convalescent plasma samples, which are ready to be further evaluated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Shenzhen Weiwu Guangming Biological Products Co. Ltd., Guangdong, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Yi-Wu</ForeName><Initials>YW</Initials></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Jiling</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xin</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Kwok</LastName><ForeName>Sui Yi</ForeName><Initials>SY</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Xiaowu</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Sai Wah</ForeName><Initials>SW</Initials></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Bing-Lou</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><CollectiveName>SARSIg Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transfusion</MedlineTA><NlmUniqueID>0417360</NlmUniqueID><ISSNLinking>0041-1132</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005916">Globulins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003289" MajorTopicYN="Y">Convalescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019281" MajorTopicYN="N">Dimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019084" MajorTopicYN="N">Fluorescent Antibody Technique, Indirect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005916" MajorTopicYN="N">Globulins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007275" MajorTopicYN="N">Injections, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010949" MajorTopicYN="N">Plasma</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>7</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>8</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>7</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15987362</ArticleId><ArticleId IdType="pii">TRF00179</ArticleId><ArticleId IdType="doi">10.1111/j.1537-2995.2005.00179.x</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>République populaire de Chine</li></country></list><tree><noCountry><name sortKey="Hong, Jiling" sort="Hong, Jiling" uniqKey="Hong J" first="Jiling" last="Hong">Jiling Hong</name><name sortKey="Huang, Xiaowu" sort="Huang, Xiaowu" uniqKey="Huang X" first="Xiaowu" last="Huang">Xiaowu Huang</name><name sortKey="Kwok, Sui Yi" sort="Kwok, Sui Yi" uniqKey="Kwok S" first="Sui Yi" last="Kwok">Sui Yi Kwok</name><name sortKey="Wong, Bing Lou" sort="Wong, Bing Lou" uniqKey="Wong B" first="Bing-Lou" last="Wong">Bing-Lou Wong</name><name sortKey="Wong, Sai Wah" sort="Wong, Sai Wah" uniqKey="Wong S" first="Sai Wah" last="Wong">Sai Wah Wong</name><name sortKey="Xie, Yi Wu" sort="Xie, Yi Wu" uniqKey="Xie Y" first="Yi-Wu" last="Xie">Yi-Wu Xie</name><name sortKey="Zhang, Xin" sort="Zhang, Xin" uniqKey="Zhang X" first="Xin" last="Zhang">Xin Zhang</name></noCountry><country name="République populaire de Chine"><noRegion><name sortKey="Zhang, Zhan" sort="Zhang, Zhan" uniqKey="Zhang Z" first="Zhan" last="Zhang">Zhan Zhang</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002559 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002559 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:15987362
|texte= Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:15987362" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |